{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:38:11Z","timestamp":1791347891080,"version":"4.3.1"},"reference-count":68,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.3892\/or.2013.2541","type":"journal-article","created":{"date-parts":[[2013,6,19]],"date-time":"2013-06-19T06:08:22Z","timestamp":1371622102000},"page":"1019-1029","source":"Crossref","is-referenced-by-count":132,"title":["Hereditary breast and ovarian cancer susceptibility genes (Review)"],"prefix":"10.3892","volume":"30","author":[{"given":"HIROSHI","family":"KOBAYASHI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SUMIRE","family":"OHNO","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YOSHIKAZU","family":"SASAKI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MIYUKI","family":"MATSUURA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2013,6,19]]},"reference":[{"key":"key20180107223146_b1-or-30-03-1019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00348188","article-title":"Hereditary breast cancer and family cancer syndromes","volume":"18","author":"Lynch","year":"1994","journal-title":"World J Surg"},{"key":"key20180107223146_b2-or-30-03-1019","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S0140-6736(94)91578-4","article-title":"Risks of cancer in BRCA1-mutation carriers","volume":"343","author":"Ford","year":"1994","journal-title":"Lancet"},{"key":"key20180107223146_b3-or-30-03-1019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.32607\/20758251-2010-2-4-31-35","article-title":"Hereditary breast-ovarian cancer syndrome in Russia","volume":"2","author":"Sokolenko","year":"2010","journal-title":"Acta Nat"},{"key":"key20180107223146_b4-or-30-03-1019","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/PPO.0b013e318238f579","article-title":"BRCA mutation testing in determining breast cancer therapy","volume":"17","author":"Smith","year":"2011","journal-title":"Cancer J"},{"key":"key20180107223146_b5-or-30-03-1019","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/path.2902","article-title":"Genetic polymorphisms in AURKA and BRCA1 are associated with breast cancer susceptibility in a Chinese Han population","volume":"225","author":"Ruan","year":"2011","journal-title":"J Pathol"},{"key":"key20180107223146_b6-or-30-03-1019","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1470-2045(11)70076-6","article-title":"Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence","volume":"12","author":"Zhang","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20180107223146_b7-or-30-03-1019","first-page":"445","article-title":"BRCA1 and BRCA2 mutations and breast cancer","volume":"12","author":"Narod","year":"2011","journal-title":"Discov Med"},{"key":"key20180107223146_b8-or-30-03-1019","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-2350-8-32","article-title":"High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic","volume":"8","author":"Vasickova","year":"2007","journal-title":"BMC Med Genet"},{"key":"key20180107223146_b9-or-30-03-1019","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ccr.2007.01.010","article-title":"Ten genes for inherited breast cancer","volume":"11","author":"Walsh","year":"2007","journal-title":"Cancer Cell"},{"key":"key20180107223146_b10-or-30-03-1019","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2407-7-152","article-title":"The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers","volume":"7","author":"Friedenson","year":"2007","journal-title":"BMC Cancer"},{"key":"key20180107223146_b11-or-30-03-1019","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1471-2407-10-90","article-title":"Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer","volume":"10","author":"Cortesi","year":"2010","journal-title":"BMC Cancer"},{"key":"key20180107223146_b12-or-30-03-1019","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"key20180107223146_b13-or-30-03-1019","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1590\/S1415-47572012000400009","article-title":"Prevalence of 185delAG and 5382insC mutations in BRCA1, and 6174delT in BRCA2 in women of Ashkenazi Jewish origin in southern Brazil","volume":"35","author":"Dillenburg","year":"2012","journal-title":"Genet Mol Biol"},{"key":"key20180107223146_b14-or-30-03-1019","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1590\/S1415-47572009005000049","article-title":"Genomic rearrangements in BRCA1 and BRCA2: a literature review","volume":"32","author":"Ewald","year":"2009","journal-title":"Genet Mol Biol"},{"key":"key20180107223146_b15-or-30-03-1019","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107223146_b16-or-30-03-1019","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-10-2560","article-title":"Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer","volume":"17","author":"Gonzalez-Angulo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107223146_b17-or-30-03-1019","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-2407-9-86","article-title":"The prevalence of BRCA1 mutations among young women with triple-negative breast cancer","volume":"9","author":"Young","year":"2009","journal-title":"BMC Cancer"},{"key":"key20180107223146_b18-or-30-03-1019","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1158\/0008-5472.CAN-08-3426","article-title":"High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer","volume":"69","author":"Holstege","year":"2009","journal-title":"Cancer Res"},{"key":"key20180107223146_b19-or-30-03-1019","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1158\/1940-6207.CAPR-10-0266","article-title":"Microscopic and early-stage ovarian cancers in BRCA1\/2 mutation carriers: building a model for early BRCA-associated tumorigenesis","volume":"4","author":"Yates","year":"2011","journal-title":"Cancer Prev Res"},{"key":"key20180107223146_b20-or-30-03-1019","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.2174\/138161212802002823","article-title":"The role of PARP inhibitors in the treatment of ovarian carcinomas","volume":"18","author":"Tinker","year":"2012","journal-title":"Curr Pharm Des"},{"key":"key20180107223146_b21-or-30-03-1019","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"},{"key":"key20180107223146_b22-or-30-03-1019","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107223146_b23-or-30-03-1019","first-page":"47","article-title":"ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer","volume":"4","author":"Vaezi","year":"2011","journal-title":"Pharmgenomics Pers Med"},{"key":"key20180107223146_b24-or-30-03-1019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/gte.2006.10.281","article-title":"Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer","volume":"10","author":"Chen","year":"2006","journal-title":"Genet Test"},{"key":"key20180107223146_b25-or-30-03-1019","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/0008-5472.CAN-07-2418","article-title":"Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer","volume":"68","author":"Potapova","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107223146_b26-or-30-03-1019","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.molonc.2009.02.004","article-title":"Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management","volume":"3","author":"Lynch","year":"2009","journal-title":"Mol Oncol"},{"key":"key20180107223146_b27-or-30-03-1019","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"key20180107223146_b28-or-30-03-1019","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1470-2045(06)70983-4","article-title":"Hereditary Ovarian Cancer Clinical Study Group: reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study","volume":"8","author":"McLaughlin","year":"2007","journal-title":"Lancet Oncol"},{"key":"key20180107223146_b29-or-30-03-1019","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1055-9965.EPI-04-0376","article-title":"Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations","volume":"14","author":"Milne","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107223146_b30-or-30-03-1019","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3892\/or.2010.885","article-title":"Genetic profiles distinguish different types of hereditary ovarian cancer","volume":"24","author":"Domanska","year":"2010","journal-title":"Oncol Rep"},{"key":"key20180107223146_b31-or-30-03-1019","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/bcr3205","article-title":"Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases","volume":"14","author":"Lotsari","year":"2012","journal-title":"Breast Cancer Res"},{"key":"key20180107223146_b32-or-30-03-1019","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/107327480901600103","article-title":"Endometrial cancer and Lynch syndrome: clinical and pathologic considerations","volume":"16","author":"Meyer","year":"2009","journal-title":"Cancer Control"},{"key":"key20180107223146_b33-or-30-03-1019","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2174\/138920211794520169","article-title":"Carcinoma of the lower uterine segment (LUS): clinicopathological characteristics and association with lynch syndrome","volume":"12","author":"Masuda","year":"2011","journal-title":"Curr Genomics"},{"key":"key20180107223146_b34-or-30-03-1019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10689-005-6573-2","article-title":"Survival of patients with ovarian cancer due to a mismatch repair defect","volume":"4","author":"Crijnen","year":"2005","journal-title":"Fam Cancer"},{"key":"key20180107223146_b35-or-30-03-1019","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3802\/jgo.2011.22.4.233","article-title":"Synchronous gynecologic malignancy and preliminary results of Lynch syndrome","volume":"22","author":"Kim","year":"2011","journal-title":"J Gynecol Oncol"},{"key":"key20180107223146_b36-or-30-03-1019","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1093\/hmg\/ddr366","article-title":"Functional and physical interaction between the mismatch repair and FA-BRCA pathways","volume":"20","author":"Williams","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key20180107223146_b37-or-30-03-1019","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"National Surgical Adjuvant Breast and Bowel Project: Update of the National Surgical Adjuvant Breast and Bowel Project Study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res"},{"key":"key20180107223146_b38-or-30-03-1019","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/bcr2850","article-title":"Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice","volume":"13","author":"Burga","year":"2011","journal-title":"Breast Cancer Res"},{"key":"key20180107223146_b39-or-30-03-1019","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-3-642-10858-7_13","article-title":"Chemoprevention of hormone receptor-negative breast cancer: new approaches needed","volume":"188","author":"Uray","year":"2011","journal-title":"Recent Results Cancer Res"},{"key":"key20180107223146_b40-or-30-03-1019","article-title":"Clinicopathological study of non-palpable familial breast cancer detected by screening mammography and diagnosed as DCIS","author":"Saito","year":"2012","journal-title":"Breast Cancer"},{"key":"key20180107223146_b41-or-30-03-1019","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00330-010-1890-8","article-title":"Detection of non-palpable breast cancer in asymptomatic women by using unenhanced diffusion-weighted and T2-weighted MR imaging: comparison with mammography and dynamic contrast-enhanced MR imaging","volume":"21","author":"Yabuuchi","year":"2011","journal-title":"Eur Radiol"},{"key":"key20180107223146_b42-or-30-03-1019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/bjc.2012.204","article-title":"Long-term results of screening with magnetic resonance imaging in women with BRCA mutations","volume":"107","author":"Passaperuma","year":"2012","journal-title":"Br J Cancer"},{"key":"key20180107223146_b43-or-30-03-1019","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J Clin Oncol"},{"key":"key20180107223146_b44-or-30-03-1019","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1002\/cncr.25820","article-title":"Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma","volume":"117","author":"Westin","year":"2011","journal-title":"Cancer"},{"key":"key20180107223146_b45-or-30-03-1019","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1042\/BJ20110314","article-title":"BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1","volume":"441","author":"Dohrn","year":"2012","journal-title":"Biochem J"},{"key":"key20180107223146_b46-or-30-03-1019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2407-12-8","article-title":"Frequency of CDH1 germline mutations in gastric carcinoma coming from high- and low-risk areas: metanalysis and systematic review of the literature","volume":"12","author":"Corso","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107223146_b47-or-30-03-1019","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PPO.0b013e31826246dc","article-title":"Genetic testing by cancer site: stomach","volume":"18","author":"Chun","year":"2012","journal-title":"Cancer J"},{"key":"key20180107223146_b48-or-30-03-1019","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1677\/ERC-09-0057","article-title":"Reproductive disturbances in multiple neuroendocrine tumor syndromes","volume":"16","author":"Lytras","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"key20180107223146_b49-or-30-03-1019","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1897-4287-10-5","article-title":"Challenges in the management of a patient with Cowden syndrome: case report and literature review","volume":"10","author":"Melb\u0101rde-Gorku\u0161a","year":"2012","journal-title":"Hered Cancer Clin Pract"},{"key":"key20180107223146_b50-or-30-03-1019","first-page":"831","article-title":"The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer","volume":"7","author":"Buller","year":"2001","journal-title":"Clin Cancer Res"},{"key":"key20180107223146_b51-or-30-03-1019","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/aps.2009.20","article-title":"Induction of G2\/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway","volume":"30","author":"Meng","year":"2009","journal-title":"Acta Pharmacol Sin"},{"key":"key20180107223146_b52-or-30-03-1019","doi-asserted-by":"crossref","first-page":"R401","DOI":"10.1186\/bcr806","article-title":"Frequency of the ATM IVS10-6T>G variant in Australian multiple-case breast cancer families","volume":"6","author":"Lindeman","year":"2004","journal-title":"Breast Cancer Res"},{"key":"key20180107223146_b53-or-30-03-1019","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1128\/MCB.02357-06","article-title":"Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia\/BRCA pathway","volume":"27","author":"Wang","year":"2007","journal-title":"Mol Cell Biol"},{"key":"key20180107223146_b54-or-30-03-1019","doi-asserted-by":"crossref","first-page":"R20","DOI":"10.1186\/bcr2832","article-title":"Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1\/2-founder mutation-negative breast and\/or ovarian cancer individuals","volume":"13","author":"Kuusisto","year":"2011","journal-title":"Breast Cancer Res"},{"key":"key20180107223146_b55-or-30-03-1019","article-title":"Low prevalence of SLX4 loss-of-function mutations in non-BRCA1\/2 breast and\/or ovarian cancer families","author":"de Garibay","year":"2012","journal-title":"Eur J Hum Genet"},{"key":"key20180107223146_b56-or-30-03-1019","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ng1902","article-title":"Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles","volume":"38","author":"Seal","year":"2006","journal-title":"Nat Genet"},{"key":"key20180107223146_b57-or-30-03-1019","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.0811159106","article-title":"PALB2 is an integral component of the BRCA complex required for homologous recombination repair","volume":"106","author":"Sy","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180107223146_b58-or-30-03-1019","doi-asserted-by":"crossref","first-page":"821529","DOI":"10.1155\/2008\/821529","article-title":"Biomarkers and mechanisms of FANCD2 function","volume":"2008","author":"Willers","year":"2008","journal-title":"J Biomed Biotechnol"},{"key":"key20180107223146_b59-or-30-03-1019","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm.2377","article-title":"Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition","volume":"17","author":"Johnson","year":"2011","journal-title":"Nat Med"},{"key":"key20180107223146_b60-or-30-03-1019","doi-asserted-by":"crossref","first-page":"e25632","DOI":"10.1371\/journal.pone.0025632","article-title":"RAD51C germline mutations in breast and ovarian cancer cases from high-risk families","volume":"6","author":"Clague","year":"2011","journal-title":"PLoS One"},{"key":"key20180107223146_b61-or-30-03-1019","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1158\/1055-9965.EPI-07-0116","article-title":"Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11\/Rad50\/Nbs1 complex","volume":"16","author":"Hsu","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key20180107223146_b62-or-30-03-1019","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ng.569","article-title":"Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene","volume":"42","author":"Meindl","year":"2010","journal-title":"Nat Genet"},{"key":"key20180107223146_b63-or-30-03-1019","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1093\/hmg\/ddr229","article-title":"RAD51C is a susceptibility gene for ovarian cancer","volume":"20","author":"Pelttari","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key20180107223146_b64-or-30-03-1019","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10689-012-9563-1","article-title":"Low penetrance alleles as risk modifiers in familial and sporadic breast cancer","volume":"11","author":"Esteban Carde\u00f1osa","year":"2012","journal-title":"Fam Cancer"},{"key":"key20180107223146_b65-or-30-03-1019","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2007.11.029","article-title":"The VEGF_936_C>T 3\u2032UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women","volume":"262","author":"Jakubowska","year":"2008","journal-title":"Cancer Lett"},{"key":"key20180107223146_b66-or-30-03-1019","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00008571-200110000-00010","article-title":"Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives","volume":"11","author":"Runnebaum","year":"2001","journal-title":"Pharmacogenetics"},{"key":"key20180107223146_b67-or-30-03-1019","doi-asserted-by":"crossref","first-page":"6509","DOI":"10.1158\/0008-5472.CAN-10-0689","article-title":"A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk","volume":"70","author":"Ratner","year":"2010","journal-title":"Cancer Res"},{"key":"key20180107223146_b68-or-30-03-1019","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ejhg.2008.212","article-title":"Breast cancer susceptibility: current knowledge and implications for genetic counselling","volume":"17","author":"Ripperger","year":"2009","journal-title":"Eur J Hum Genet"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2013.2541\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T18:56:36Z","timestamp":1595962596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2013.2541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,19]]},"references-count":68,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2013,6,19]]},"published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.3892\/or.2013.2541"],"URL":"https:\/\/doi.org\/10.3892\/or.2013.2541","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,19]]}}}